Press Releases

Date Title and Summary Additional Formats
Toggle Summary Harvard Bioscience Announces Fourth Quarter 2020 Financial Results
Sales effectiveness focus with disciplined cost management results in improved revenues and margins while reducing debt Revenue returns to pre-Covid19 levels on strong CRO/pharma sales Operating margin increased year-over-year on GAAP and an adjusted basis New debt facility significantly reduces
View HTML
Toggle Summary Harvard Bioscience Schedules Fourth Quarter 2020 Earnings Conference Call for March 10, 2021 at 8:00 AM ET
HOLLISTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2020 before the market opens on March 10, 2021, and will hold a conference call to discuss the results on March 10, 2021 at 8:00 a.m.
View HTML
Toggle Summary Harvard Bioscience Announces New Credit Facility
Improves liquidity and operating flexibility Significantly reduces borrowing costs Supports ongoing transformation to profitable growth platform HOLLISTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (“Harvard Bioscience”) today announced the refinancing of its
View HTML
Toggle Summary Harvard Bioscience to attend Benchmark’s 9th Annual Discovery One-on-One Conference
HOLLISTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green, Chairman, President and CEO, and Michael Rossi, CFO will participate in The Benchmark Company’s 9th Annual Discovery One-on-One Conference.
View HTML
Toggle Summary Harvard Bioscience Announces Third Quarter 2020 Financial Results
Disciplined cost management, cash conservation actions drive increased year-over-year operating income and reduced net debt Operating margin up year-over-year on GAAP and adjusted basis Revenue improved sequentially with solid CRO/pharma demand and academic labs reopening Generated positive
View HTML
Toggle Summary Harvard Bioscience Schedules Third Quarter 2020 Earnings Conference Call for November 5, 2020 at 8:00 AM ET
HOLLISTON, MA. , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2020 before the market opens on November 5, 2020 , and will hold a conference call to discuss the results on November 5, 2020 at 8:00
View HTML
Toggle Summary Harvard Bioscience to Present at Singular Research Compelling Values Webinar
HOLLISTON, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, President and CEO, will present at the Singular Research Compelling Values 2020 Webinar on September 17, 2020 at 2:15  p.m. ET.
View HTML
Toggle Summary Harvard Bioscience Announces Second Quarter 2020 Financial Results
Accelerated cost reduction, cash conservation actions drive increased operating income, reduced net debt Operating Income up sequentially and year-over-year on both GAAP and adjusted basis Cost reduction programs offset expected declines in Academic markets Net Debt reduced by $2.2 million in Q2
View HTML
Toggle Summary Harvard Bioscience Schedules Second Quarter 2020 Earnings Conference Call for August 5, 2020 at 8:00 AM ET
HOLLISTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2020 before the market opens on August 5, 2020, and will hold a conference call to discuss the results on August 5, 2020 at 8:00 a.m.
View HTML
Toggle Summary Harvard Bioscience, Inc. Issues Letter to Shareholders
Provides Update on Performance Against Previously Announced Strategic Plan HOLLISTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Jim Green, Chairman, President & Chief Executive Officer of Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today issued a letter to
View HTML